Andrew Peters

Andrew Peters has a solid background in the biotechnology industry. Andrew currently serves as the Senior Vice President of Strategy at Exelixis, a position they have held since May 2018. Prior to that, Andrew worked at Deutsche Bank as the Director of Biotechnology Equity Research from May 2016 to May 2018. Andrew also spent several years at UBS Investment Bank as an Equity Research Analyst focusing on biotechnology from March 2009 to April 2016. Andrew gained further experience in equity research at Susquehanna International Group as an Equity Research Associate from February 2008 to November 2008 and at Morgan Joseph & Co. from 2006 to 2008. In addition, they worked as a Business Development Intern at Amylin Pharmaceuticals from May 2005 to June 2006 and as a Business Analyst at Patpatia & Associates in 2004.

Andrew Peters completed their undergraduate education at Claremont McKenna College from 2000 to 2004. Andrew obtained a Bachelor's degree in Economics and Molecular Biology. From 2004 to 2006, they attended the Keck Graduate Institute of Applied Life Sciences, although it is unclear whether they earned a degree or pursued a specific field of study during this time.